Literature DB >> 11041171

The pathophysiology of mitral regurgitation.

B A Carabello1.   

Abstract

The results of treatment of heart valve disease have improved steadily during the past 20 years. In aortic stenosis, although postoperative survival rates approximated those of age-matched controls, the outcome of surgery to treat ischemic and non-ischemic mitral regurgitation was grave. The reasons for this were two-fold: first, patients were referred for surgery late in the course of their disease, when irreversible left ventricular (LV) dysfunction prevented postoperative restoration of contractile function. Second, the value of the mitral valve apparatus in facilitating LV contraction was unrecognized, and this structure was often removed at surgery, in turn worsening pre-existent LV dysfunction. Consequently, patients with LV dysfunction due to mitral regurgitation underwent surgery that caused further damage to the left ventricle. Not surprisingly, postoperative LV function was poor, congestive heart failure persistent, and lifespan shortened. More recently, however, substantial insight has been gained into the value of the mitral valve apparatus, the causes of LV dysfunction in mitral regurgitation, and into the objective markers of LV function that permit the clinician to recommend surgery before muscle dysfunction has become severe and irreversible.

Entities:  

Mesh:

Year:  2000        PMID: 11041171

Source DB:  PubMed          Journal:  J Heart Valve Dis        ISSN: 0966-8519


  3 in total

1.  Comparison of N-terminal pro B-natriuretic Peptide and echocardiographic indices in patients with mitral regurgitation.

Authors:  Shokoufeh Hajsadeghi; Niloufar Samiei; Masoud Moradi; Maleki Majid; Ladan Kashani; Afsaneh Amani; Arezoo Salami; Melika Asefi; Negin Farsi
Journal:  Clin Med Insights Cardiol       Date:  2010-11-30

2.  The efficacy of mitral valve surgery in children with dilated cardiomyopathy and severe mitral regurgitation.

Authors:  John P Breinholt; Charles D Fraser; William J Dreyer; Anthony C Chang; E O'Brian Smith; Jeffrey S Heinle; E Dean McKenzie; Sarah K Clunie; Jeffrey A Towbin; Susan W Denfield
Journal:  Pediatr Cardiol       Date:  2007-09-11       Impact factor: 1.655

3.  B-type Natriuretic Peptide as an Index of Symptoms and Severity of Chronic Rheumatic Mitral Regurgitation.

Authors:  Eman M Abdel Fattah; Hany Younan Azer Girgis; Khaled El Khashab; Zeinab A Ashour; Ghada M Ezzat
Journal:  Heart Views       Date:  2016 Jan-Mar
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.